Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 121-132 , March 2006

The metabolic syndrome: Prevalence, CHD risk, and treatment

  • Cinzia Sarti

      Affiliations

    • National Public Health Institute, Helsinki, Finland
    • Corresponding Author InformationCorresponding author. Department of Epidemiology and Health Promotion, National Public Health Institute, Mannerheimintie 166, Helsinki FIN-00300, Finland. Tel.: +358 505 831305; fax: +358 947 448338.
    • ,
  • John Gallagher

      Affiliations

    • AstraZeneca SA, Zaventem, Belgium

Received 4 February 2004 ,Revised 1 June 2005 ,Accepted 7 June 2005.

References 

  1. Albert MA, Danielson E, Rifai N, Ridker PM for the PRINCE investigation. Effect of statin therapy on C-reactive protein levels. JAMA. 2001;286:64–70
  2. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Medicine. 1998;15:539–553
  3. ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998–3007
  4. Andrews T, Ballantyne CM, Hsia J, Kramer J. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. American Journal of Medicine. 2001;111:185–191
  5. Ansell BJ, Watson KE, Weiss RE, Fonarow GC. HsCRP and HDL effects of statins trial (CHEST): Rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels. A clinical investigation. Heart Disease. 2003;5:2–7
  6. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) Study: Prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. American Heart Journal. 1988;116:1713–1724
  7. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. European Heart Journal. 1998;19(Suppl. M):M8–M14
  8. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridaemia as a cardiovascular risk factor. American Journal of Cardiology. 1998;81:7B–12B
  9. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. American Journal of Cardiology. 2003;92:27J–33J
  10. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275:128–133
  11. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, Yudkin JS, et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes & Metabolism. 2002;28:364–376
  12. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104:3046–3051
  13. Ballantyne CM, Stein EA, Paoletti R, Southworth H, Blasetto JW. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. American Journal of Cardiology. 2003;91(Suppl.):25C–28C
  14. Bellosta S, Ferri N, Arnaboldi L, Bernini F, Paoletti R, Corsini A. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000;23(Suppl. 2):B72–B78
  15. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. New England Journal of Medicine. 1998;338:1650–1656
  16. Bonora E, Targher G, Zenere MB, Saffiani F, Cacciatori V, Tosi F, et al. Relationship between fasting insulin and cardiovascular risk factors is already present in young men: The Verona Young Men Atherosclerosis Risk Factors Study. European Journal of Clinical Investigation. 1997;27:248–254
  17. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. New England Journal of Medicine. 2004;350:1505–1515
  18. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, and antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine. 2001;345:1583–1592
  19. Chaiyakunapruk N, Boudreau D, Ramsey SD. Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes. Journal of Cardiovascular Risk. 2001;8:127–132
  20. Cohen JD, Eberly LE, Prineas R, Vasquez G. The influence of the metabolic syndrome in 24-year mortality among middle-aged men in the Multiple Risk Factor Intervention Trial (MRFIT). Journal of the American College of Cardiology. 2003;41(Suppl. A):291A
  21. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696
  22. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Journal of Cardiovascular Prevention and Rehabilitation. 2003;10(Suppl. 1):S2–S78
  23. De Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low-density lipoprotein subfraction in healthy subjects. Arteriosclerosis and Thrombosis. 1991;11:298–306
  24. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ. 2001;322:716–720
  25. Drake AJ, Smith A, Betts PR, Crowne EC, Shield JP. Type 2 diabetes in obese white children. Archives of Disease in Childhood. 2002;86:207–208
  26. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research and Clinical Practice. 2004;64:137–151
  27. Egan BM. Insulin resistance and the sympathetic nervous system. Current Hypertension Reports. 2003;5:247–254
  28. Ehtisham S, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children—An emerging problem. Diabetic Medicine. 2000;17:867–871
  29. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European action on secondary prevention by intervention to reduce events. Lancet. 2001;357:995–1001
  30. Evans A, Tolonen H, Hense HW, Ferrario M, Sans S, Kuulasmaa K. Trends in coronary risk factors in the WHO MONICA project. International Journal of Epidemiology. 2001;30(Suppl. 1):S35–S40
  31. Everson SA, Goldberg DE, Helmrich SP, Lakka TA, Lynch JW, Kaplan GA, et al. Weight gain and the risk of developing insulin resistance syndrome. Diabetes Care. 1998;21:1637–1643
  32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  33. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, et al. Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. Journal of Pediatrics. 2000;136:664–672
  34. Falkner B, Hassink S, Ross J, Gidding S. Dysmetabolic syndrome: Multiple risk factors for premature adult disease in an adolescent girl. Pediatrics. 2002;110:e14
  35. Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003;26:575–581
  36. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA. 2002;287:356–359
  37. Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome. Diabetes Care. 2000;23:1835–1839
  38. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Current Controlled Trials Cardiovascular Medicine. 2001;2:205–207
  39. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidaemia, and the metabolic syndrome. American Journal of Cardiology. 1998;81:18B–25B
  40. Grundy SM. Hypertriglyceridemia, insulin resistance and the metabolic syndrome. American Journal of Cardiology. 1999;83:25F–29F
  41. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New England Journal of Medicine. 1998;339:229–234
  42. Hayden MR, Tyagi SC. Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovascular Diabetology. 2002;1:3
  43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 2003;361:2005–2016
  44. Holman RR, Wheeler F, Cull CA, Manley SE, Keenan J, Neil HAW. Combination statin and fibrate therapy in type 2 diabetes: Results from the Lipids in Diabetes Study. Diabetic Medicine. 2003;20(Suppl. 2):16
  45. Holvoet P, Kritchevsky SB, Tracy RP, Cummings S, Goodpaster B, Harris TB. The metabolic syndrome is associated with elevated circulating oxidised LDL in the health, aging and body composition cohort. Circulation. 2002;106(Suppl. II):A3594
  46. Hunninghake DB, Ballantyne CM, Maccubin DL, Shah AK, Gumbiner B, Mitchel YB. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clinical Therapeutics. 2003;25:1670–1686
  47. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–689
  48. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obesity Research. 2001;9(Suppl. 4):228S–233S
  49. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). American Journal of Cardiology. 2003;92:152–160
  50. Juhan-Vague I, Thompson SG, Jesperson J on behalf of the ECAT Angina Pectors Study Group. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arteriosclerosis and Thrombosis. 1993;13:1865–1873
  51. Kang HS, Gutin B, Barbeau P, Litaker MS, Allison J, Le NA. Low-density lipoprotein particle size, central obesity, cardiovascular fitness, and insulin resistance syndrome markers in obese youths. International Journal of Obesity and Related Metabolic Disorders. 2002;26:1030–1035
  52. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Archives of Internal Medicine. 1989;149:1514–1520
  53. Kaufman FR. Type 2 diabetes mellitus in children and youth: A new epidemic. Journal of Pediatric Endocrinology & Metabolism. 2002;15(Suppl. 2):737–744
  54. Kavey RE, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation. 2003;107:1562–1566
  55. Keaney JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: Clinical correlates of oxidative stress in the Framingham Study. Arteriosclerosis Thrombosis and Vascular Biology. 2003;23:434–439
  56. Keech A, Colquhoun D, Best J, Kirby A, John Simes R, Hunt D, et al. Diabetes Care. 2003;26:2713–2721
  57. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: Prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414–1431
  58. Kortelainen ML, Särkioja T. Coronary atherosclerosis associated with body structure and obesity in 599 women aged between 15 and 50 years. International Journal of Obesity and Related Metabolic Disorders. 1999;23:838–844
  59. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  60. Lakka HM, Lakka TA, Tuomilehto J, Salonen JT. Abdominal obesity is associated with increased risk of acute coronary events in men. European Heart Journal. 2002;23:706–713
  61. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow up of participants in the population study of women in Gothenburg, Sweden. BMJ (Clinical Research Ed.). 1984;289:1257–1261
  62. Laufs U. Beyond lipid lowering: Effects of statins on endothelial nitric oxide. European Journal of Clinical of Pharmacology. 2003;58:719–731
  63. Liao J. Beyond lipid lowering: The role of statins in vascular protection. International Journal of Cardiology. 2002;86:5–18
  64. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143
  65. L'Italien G, Ford I, Shepherd J. The metabolic syndrome is an independent predictor of cardiac events in WOSCOPS males. Journal of the American College of Cardiology. 2003;41(Suppl. A):291A
  66. Lopes C, Dina C, Durand E, Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population. Diabetologia. 2003;46:1284–1290
  67. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129–135
  68. Manolio TA, Savage PJ, Burke GL, Liu KA, Wagenknecht LE, Sidney S, et al. Association of fasting insulin with blood pressure and lipids in young adults. The CARDIA study. Arteriosclerosis. 1990;10:430–436
  69. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000;101:207–213
  70. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. American Journal of Cardiology. 2001;88:270–274
  71. Monti LD, BArlassina C, Citterio L, Gallucio E, Berzuini C, Setola E, et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome. Diabetes. 2003;52:1270–1275
  72. Mora S, Blumenthal RS, Yanek LR, Moy TF, Becker LC, Becker DM. Elevated C-reactive protein in high-risk asymptomatic individuals is strongly associated with the metabolic syndrome. Journal of the American College of Cardiology. 2003;41(Suppl. A):292A
  73. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3. Journal of Lipid Research. 2000;41:1495–1508
  74. Navab M, Hama SY, Cooke CJ, Anantharamaiah GM, Chaddha M, Jin L, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1. Journal of Lipid Research. 2000;41:1481–1494
  75. Nilsson PM, Hedblad B. Prevalence of the metabolic syndrome: Impact on cardiovascular risk epidemiology—A population-based study from Malmö, Sweden. Heart Drug. 2002;273–278
  76. Nilsson TK, Boman K, Bjerle P, Hallamns G, Hellsten G. Von Willibrand factor and fibrinolytic variables are differentially affected in the insulin resistance syndrome. Journal of Internal Medicine. 1994;235:419–423
  77. Ninomiya JK, L'Italien GJ, Criqui MH, Whyte JL, Gamst A, Chen RS. The association of the metabolic syndrome with myocardial infarction and stroke in the National Health and Nutrition Examination Survey III. Journal of the American College of Cardiology. 2003;41(Suppl. A):292A
  78. Pan J, Lin M, Kesala RL, Van J, Charles MA. Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obesity & Metabolism. 2002;4:255–261
  79. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome. Prevalence and associated risk factor findings in the US population from the Third National Health And Nutrition Examination Survey 1988–1994. Archives of Internal Medicine. 2003;163:427–436
  80. Prineas RJ, Folsom AR, Kaye SA. Central adiposity and increased risk of coronary artery disease mortality in older women. Annals of Epidemiology. 1993;3:35–41
  81. Pyörälä K, Pederson TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620
  82. Rayner M, Petersen S. European cardiovascular disease statistics. London: British Heart Foundation; 2000;
  83. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  84. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiological Reviews. 1995;75:473–486
  85. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14719 initially healthy American women. Circulation. 2003;107:391–397
  86. Ridker PM, Rifai MPH, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New England Journal of Medicine. 2001;344:1959–1965
  87. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E for the Cholesterol and Recurrent Events (CARE) Investigators. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
  88. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. American Journal of Epidemiology. 1995;141:1117–1127
  89. Rönnemaa T, Knip M, Lautala P, Viikari J, Uhari M, Leino A, et al Serum insulin and other cardiovascular risk indicators in children, adolescents and young adults. Annals of Medicine. 1991;23:67–72
  90. Rosenson RS. Statins in atherosclerosis: Lipid-lowering agents with antioxidant capabilities. Atherosclerosis. 2004;173:1–12
  91. Rosenson RS. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome. Current Problems in Cardiology. 2005;30:241–279
  92. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA. 1998;279:1643–1650
  93. Rössner S. Obesity: The disease of the twenty-first century. International Journal of Obesity and Related Metabolic Disorders. 2002;26(Suppl. 4):S2–S4
  94. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. New England Journal of Medicine. 1999;341:410–418
  95. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project Investigators Group. Circulation. 2000;102:1893–1900
  96. Sakkinen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH, et al. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arteriosclerosis Thrombosis and Vascular Biology. 1999;19:499–504
  97. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American Journal of Epidemiology. 2000;152:897–907
  98. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation. 2003;108:414–419
  99. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149–1158
  100. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronary artery disease risk: A comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. American Journal of Cardiology. 2003;91:11C–17C
  101. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). Journal of Internal Medicine. 2002;252:440–447
  102. Sinaiko AR, Donahue RP, Jacobs DR, Prineas RJ. Relation of weight and rate of increase in weight during childhood and adolescence to body size, blood pressure, fasting insulin, and lipids in young adults. The Minneapolis Children's Blood Pressure Study. Circulation. 1999;99:1471–1476
  103. Sinha R, Fisch G, Teague B, Tamborlane WV, Banyas B, Allen K, et al. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. New England Journal of Medicine. 2002;46:802–810
  104. Sowers JR. Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. American Journal of Cardiology. 2003;91:14B–22B
  105. Stalenhoef AFH, Ballantyne CM, Sarti C, Wilpshaar W, Southworth H. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: Rationale and design of the COMETS study. Diabetes & Metabolism. 2003;29(Suppl.):4S318;(abstract number 2559)
  106. Stalenhoef AFH, Ballantyne CM, Tuomilehto J, Murin J, Tonstad S, Rose H, et al. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: Results of the COMETS study. Diabetologia. 2004;47:A409–A410
  107. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  108. Stein E, Lane M, Laskarzewski P. Comparison of statins in hypertriglyceridemia. American Journal of Cardiology. 1998;81(Suppl. 4A):66B–69B
  109. Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, et al. Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. American Journal of Cardiology. 2000;86:406–411
  110. Steinberger J, Daniels SR. Obesity, insulin resistance, diabetes, and cardiovascular risk in children: An American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism). Circulation. 2003;107:1448–1453
  111. St-Pierre J, Lemieux I, Vohl MC, Perron P, Tremblay G, Després JP, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. American Journal of Cardiology. 2002;90:15–18
  112. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002;287:1420–1426
  113. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis. 1992;93:189–199
  114. Ulmer H, Kelleher C, Diem G, Concin H. Long-term tracking of cardiovascular risk factors among men and women in a large population-based health system. European Heart Journal. 2003;24:1004–1013
  115. Vanhala M, Vanhala P, Kumpusalo E, Halonen P, Takala J. Relation between obesity from childhood to adulthood and the metabolic syndrome: Population based study. BMJ. 1998;317:319–320
  116. Vanhala MJ, Kumpusalo EA, Pitkajarvi TK, Takala JK. Metabolic syndrome in a middle-aged Finnish population. Journal of Cardiovascular Risk. 1997;4:291–295
  117. Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. American Journal of Cardiology. 2003;91:956–960
  118. Wang JJ, Qiao Q, Miettinen ME, Lappailainen J, Hu G, Tuomilehto J. The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care. 2003;27:242–2437
  119. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin rsistance on vascular endothelial function. Diabetic Medicine. 2003;20:255–268
  120. Williams CL, Hayman LL, Daniels SR, Robinson TN, Steinberger J, Paridon S, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002;106:143–160
  121. World Health Organization. Obesity: Preventing and managing the global epidemic. WHO obesity technical report series 894. Geneva, Switzerland: World Health Organization; 2000;
  122. World Health Organization . The World Health Report 2002. Reducing risks, promoting healthy life. World Health Organization; 2002;Available from: URL: http://www.who.int/whr/2002/whr2002_annex2_pdf[Accessed 11 December 2003]
  123. World Health Organization Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus. World Health Organization Department of Noncommunicable Disease Surveillance. WHO/NCD/NCS/99.2. Geneva 1999.
  124. Xydakis AM, Ballantyne CM. Combination therapy for combined dyslipidaemia. American Journal of Cardiology. 2002;90:21K–29K
  125. Youssef AA, Valdez R, Elkasabany A, Srinivasan SR, Berenson GS. Time-course of adiposity and fasting insulin from childhood to young adulthood in offspring of parents with coronary artery disease: The Bogalusa Heart Study. Annals of Epidemiology. 2002;12:553–559
  126. Zhao XQ, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). American Journal of Cardiology. 2004;93:307–312

☆ Funding for the article was supported by AstraZeneca.

PII: S1056-8727(05)00083-8

doi: 10.1016/j.jdiacomp.2005.06.014

Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 121-132 , March 2006

Article Tools

* Image Usage & Resolution